Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mimedx Group Q3 2026 Results: Net Loss of $8.68M

MiMedx Group reported a significant decline in net sales to $185.6 million for the nine months ended September 30, 2026, compared to $300.5 million in the prior year, resulting in a net loss of $34.4 million. The company's financial position was impacted by changes in Medicare reimbursement for skin substitutes and costs associated with the pending acquisition of Sanara MedTech Inc.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue62.3113.7
Gross profit49.795.0
Profit before tax-11.122.8
Net income-8.716.7
EPS (diluted, $ a share)$-0.06$0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-45.2%
Gross margin79.8%
Operating margin-18.8%
Source

10-Q filed with the SEC, NASDAQ: MDXG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mimedx Group, Inc.: key numbers

Share price
$3.18Close, Nov 16
Market cap
$464M
Shares outstanding
145.93MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mimedx Group, Inc.

All →
4:05 PM ET 8-K
Financial Results

Mimedx Group Financial Results

MiMedx Group reported Q3 2026 financial results, highlighting a 45% year-over-year revenue decline to $62 million primarily due to Medicare reimbursement changes affecting its Wound business. Despite the overall decline, the Surgical franchise grew 9% and the company returned to positive Adjusted EBITDA following cost-reduction initiatives.

“Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.”

Joseph H. Capper, MIMEDX Chief Executive Officer

“We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech. As we prepare for the combination of the two companies, our conviction in both the strategic rationale and the financial merits of this transaction remains strong,”

Joseph H. Capper, MIMEDX Chief Executive Officer
9:01 AM ET 8-K
M&A Deal

Mimedx Group M&A Deal with Sanara MedTech Inc.

MiMedx Group and Sanara MedTech each received a 'Second Request' for information from the FTC regarding their pending merger. This action extends the HSR Act waiting period until 30 days after both parties substantially comply with the request, unless terminated earlier by the regulator.

Counterparty
Sanara MedTech Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.